¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HEP"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 9 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hepatolienomegaly
    °£Áö¶óºñ´ë, °£ºñºñ´ë
  • hepatolith
    °£µ¹, °£°á¼®
  • hepatolithectomy
    °£µ¹Á¦°Å(¼ú), °£°á¼®Á¦°Å(¼ú)
  • hepatolithiasis
    °£µ¹Áõ, °£°á¼®Áõ
  • hepatology
    °£ÇÐ
  • hepatoma
    °£¾Ï
  • hepatomalacia
    °£¿¬È­(Áõ)
  • hepatomegaly
    °£ºñ´ë
  • hepatomelanosis
    °£Èæ»öÁõ, °£¸á¶ó´ÑÁõ
  • hepatomphalocele
    °£¹è²ÅÅ»Àå
  • hepatomphalos
    °£¹è²Åµ¹Ãâ
  • hepatonephric
    °£ÄáÆÏ-, °£½Å(ÊÜãì)-
  • hepatonephromegaly
    °£ÄáÆÏºñ´ë, °£½Åºñ´ë
  • hepatopancreas
    °£ÀÌÀÚ, °£ÃéÀå
  • hepatopancreatic ampulla
    ¾µ°³ÀÌÀÚ°üÆØ´ë, °£Ã鯨´ë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hepatolienal
    °£Áö¶ó-, °£ºñÀå-
  • hepatolienal disease
    °£Áö¶óº´, °£ºñÀ庴
  • hepatolienography
    °£Áö¶óÁ¶¿µ¼ú, °£ºñÀåÁ¶¿µ¼ú
  • hepatolienomegaly
    °£Áö¶óºñ´ë
  • hepatolith
    °£µ¹, °£°á¼®
  • hepatolithectomy
    °£µ¹Á¦°Å¼ú, °£°á¼®Á¦°Å¼ú
  • hepatolithiasis
    °£µ¹Áõ, °£¼®Áõ
  • hepatoma
    °£¾Ï
  • hepatomalacia
    °£¿¬È­(Áõ)
  • hepatomegaly
    °£ºñ´ë
  • hepatomelanosis
    °£Èæ»öÁõ
  • hepatomphalocele
    °£¹è²ÅÇ츣´Ï¾Æ
  • hepatomphalos
    °£¹è²Åµ¹Ãâ
  • hepatonephric
    °£ÄáÆÏ-
  • hepatonephromegaly
    °£ÄáÆÏºñ´ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hepatic encephalopathy
    °£¼º ³úº´Áõ(ÊÜàõ ÒàÜ»ñø)
  • hepatic enlargement
    °£Á¾´ë(ÊÜðþÓÞ).
  • hepatic enlargement
    °£Á¾´ë(°£Á¾´ë).
  • hepatic failure
    °£ºÎÀü(ÊÜÝÕîï).
  • hepatic failure
    °£ºÎÀü(ÊÜÜôîï)
  • hepatic failure
    °£ºÎÀü(°£ºÒÀü).
  • hepatic fibrosis
    °£¼¶À¯Áõ(ÊÜàéë«ñø)
  • hepatic first pass effect
    °£ÃÊȸÅë°úÈ¿°ú.
  • hepatic fistula
    °£·ç(°£·ç).
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(¿ì°áÀå°î), °£¸¸°î(°£¸¸°î) .
  • hepatic flexure ³ª f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • Hepatic glucogenesis, in diabetes mellitus
    °£´ç»ý¼º(ÊÜÓØßæà÷)
  • hepatic glycogen
    °£(ÊÜ)±Û¸®ÄÚ°Õ.
  • hepatic gutter
    °£±¸(ÊÜϵ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • hepatic failure
    °£ºÎÀü(ÊÜÝÕîï).
  • hepatic failure
    °£ºÎÀü(ÊÜÜôîï)
  • hepatic fibrosis
    °£¼¶À¯Áõ(ÊÜàéë«ñø)
  • hepatic first pass effect
    °£ÃÊȸÅë°úÈ¿°ú.
  • hepatic fistula
    °£·ç(°£·ç).
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(¿ì°áÀå°î), °£¸¸°î(°£¸¸°î) .
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic flexure ³ª f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic glycogen
    °£(ÊÜ)±Û¸®ÄÚ°Õ.
  • hepatic gutter
    °£±¸(ÊÜϵ).
  • hepatic hilum
    °£¹®
  • hepatic infantilism
    °£¼º¼Ò¾ÆÁõ.
  • hepatic insufficiency
    °£(±â´É)ºÎÀü.
  • hepatic lipase
    °£¸®ÆÄÁ¦
  • hepatic lobes
    °£¿±
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
hepatitis A <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances.
The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio.
(27 Sep 1997)
hepatitis a immunization When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
hepatitis A virus <virology> An RNA virus (hepatovirus) in the family Picornaviridae, that is the causative agent of viral hepatitis type A.
The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the faecal-oral route.
Synonym: infectious hepatitis virus.
(20 Sep 2002)
hepatitis agents, gb Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis.
(12 Dec 1998)
hepatitis antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
(12 Dec 1998)
hepatitis antigens Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
(12 Dec 1998)
hepatitis B <virology> A form of viral hepatitis, known as serum hepatitis, because it is commonly spread through contact with infected blood products (transfusion). May also be spread sexually or from mother to infant. Hepatitis B can cause a much more severe infection than hepatitis A and can occur as an asymptomatic carrier state, a chronic infection or as cirrhosis of the liver. Those at risk (IV drug abusers, health care workers, dialysis patients, transfusion recipients, homosexuals) should be immunised with hepatitis B vaccine.
The virus is 42nm diameter, with an outer sheath enclosing inner 27nm core particle containing the circular viral DNA. Aggregates of the envelope proteins are found in plasma and are referred to as hepatitis B surface antigen (HBsAg, previously called Australia antigen). The virus can persist for long periods (and in asymptomatic carriers), association of integrated virus with hepatocellular carcinoma is now well established.
(27 Sep 1997)
hepatitis B antibodies <immunology> Antibodies to the hepatitis b antigens, including antibodies to the surface (Australia) and core of the dane particle and those to the "e" antigens.
(12 Dec 1998)
hepatitis B antigen Antigens of the virion of the hepatitis b virus or the dane particle, its surface, core and other associated antigens, like the hbe antigen.
(12 Dec 1998)
hepatitis B core antigen <virology> (HBcAb, HBcAg), the antigen found in the core of the Dane particle (which is the complete virus) and also in hepatocyte nuclei in hepatitis B infections.
(05 Mar 2000)
hepatitis B e antigen (HBeAb, HBe, HBeAg), an antigen, or group of antigen's, associated with hepatitis B infection and distinct from the surface antigen (HBsAg) and the core antigen (HBcAg); it is associated with the viral nucleocapsid. Its presence indicates that the virus is replicating and the individual is potentially infectious.
(05 Mar 2000)
hepatitis b e antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis b or in virulent chronic hepatitis b, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins g.
(12 Dec 1998)
hepatitis b immunization Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Healthcare workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
hepatitis B surface antigen <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test.
(27 Sep 1997)
hepatitis b surface antigens Those hepatitis b antigens found on the surface of the dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 7
  • Hepatitis B Antigens - »õâ Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
    Synonyms : Antigens, Hepatitis B, B Antigens, Hepatitis
  • Hepatitis B Core Antigens - »õâ The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
    Synonyms : Hepatitis B Core Antigen
  • Hepatitis B e Antigens - »õâ A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
    Synonyms : HBe Ag-1, HBe Ag-2, Hepatitis Be Antigens, Antigens, Hepatitis Be, Antigens, e, Be Antigens, Hepatitis
  • Hepatitis B Surface Antigens - »õâ Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
    Synonyms : Hepatitis B Surface Antigen, Antigen, Australia
  • Hepatitis B Vaccines - »õâ Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
    Synonyms : Hepatitis B Vaccine, Vaccine, Hepatitis B, Vaccines, Hepatitis B
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 10 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÇìÆÅ½ÅºñÁÖ»ç(½Å»ý¾Æ,¼Ò¾Æ¿ë) - »õâ
¾¾Á¦ÀÌ
Purified hepatitis B surface antigen
ÀϹÝÀǾàǰ | ºñ±Þ¿©
ÇìÆÄºñÁÖ1ml/V - »õâ
Çѱ¹¹é½Å
Purified Hepatitis B Surface Antigen Protein
Àü¹®ÀǾàǰ | ºñ±Þ¿©
ÇìÆÄºñÁÖ0.5ml/V - »õâ
Çѱ¹¹é½Å
Purified Hepatitis B Surface Antigen Protein
Àü¹®ÀǾàǰ | ±Þ¿©
ÇìÆÄºê¸´Áö¾×30ml - »õâ
»ïÁøÁ¦¾à
ÀϹÝÀǾàǰ | ºñ±Þ¿©
ÇñƼ½ººñÁÖ10ml - »õâ
º¸·É¹ÙÀÌ¿ÀÆÄ¸¶
Purified Hepatitis B Surface Antigen Protein
Àü¹®ÀǾàǰ | ºñ±Þ¿©
ÇìÆÄÅ¥¾î¿¬Áúݼ¿ - »õâ
À¯´Ï¸ÞµåÁ¦¾à
ÀϹÝÀǾàǰ | ¹Ì»ý»ê
ÇìÆÄÅ¥¶õ½Ã·´ - »õâ
À¯´Ï¸ÞµåÁ¦¾à
ÀϹÝÀǾàǰ | ºñ±Þ¿©
³ì½ÊÀÚ»ó¾ÆÇìÆÄ¸°³ªÆ®·ýÁÖ»ç¾× - »õâ
³ì½ÊÀÚ
A35540521 Heparin sodium
Àü¹®ÀǾàǰ | ±Þ¿©
ÀÌÆÅ»ìº£¸£³ªÇÁ¸®Çʵå½Ã¸°ÁöÁÖ(ÈíÂøAÇü°£¿°-ºñ·ÎÁ»¹é½Å) - »õâ
Serum & Vaccine
Hepatitis A antigen
Àü¹®ÀǾàǰ | ºñ±Þ¿©
ÇìÆÄ½Å¿¬Áúݼ¿ - »õâ
»ï¼ºÁ¦¾à
Calcium pantothenate, Carduus Marianus extract, Cyanocobalamin, Nicotinamide, Pyridoxine HCl, Thiamine nitrate
ÀϹÝÀǾàǰ | ºñ±Þ¿©
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
hepatic encephalopathy a condition usually occurring secondarily to advanced disease of the liver but also seen in the course of any severe disease or in patients with portacaval shunts. It is marked by disturbances of consciousness which may progress to deep coma (hepatic coma), psychiatric changes of varying degree, flapping tremor, and fetor hepaticus. Called also portal-systemic e.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
hepatologist is a physican who specializes in the liver and its diseases.
Ãâó: www.geocities.com/HotSprings/3982/dictionary.html
hepatorenal syndrome a combined liver and kidney failure.
Ãâó: www.geocities.com/HotSprings/3982/dictionary.html
hepatotoxic a compound that is toxic to liver cells.
Ãâó: www.geocities.com/HotSprings/3982/dictionary.html
hepatic encephalopathy is a serious complication of advanced liver disease caused by toxins, that the liver is no more able to remove from the bloodstream. It is clinically manifested by personality changes and impaired intellectual ability, awareness, and neuromuscular functioning.
Ãâó: www.geocities.com/HotSprings/3982/dictionary.html
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 7
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á